{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"melanotan-ii","urls":{"read":"https://miscsubjects.com/api/articles/melanotan-ii/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/melanotan-ii/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/melanotan-ii/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/melanotan-ii/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/melanotan-ii/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/melanotan-ii/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/melanotan-ii/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"melanotan-ii","title":"melanotan ii","register":"standard","tags":[],"updated_at":"2026-07-17T02:40:14.804Z","body_excerpt":"## Overview\nEvidence is being populated by Grok web search.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c2","text":"May 2026 listing of ongoing Phase 2 RCT (NCT07437560) testing MT-II safety and efficacy as add-on to phototherapy for vitiligo repigmentation.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"2026 case report documenting oral mucosal pigmentation changes following Melanotan II use, with follow-up observations on resolution after discontinuation.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c1","text":"2025 case report linking Melanotan II nasal spray use to oral mucosal malignant melanoma in a young female; highlights unlicensed status and need for awareness of serious side effects.","tier":"mechanistic","weight":0.3,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c3","text":"2026 case report of multiple primary melanomas in situ associated with recent Melanotan (II) exposure along with other risk factors.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40210573/","title":"Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?","quote":"The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. ... Histological analysis confirmed the diagnosis of a mucosal malignant melanoma.","summary":"2025 case report linking Melanotan II nasal spray use to oral mucosal malignant melanoma in a young female; highlights unlicensed status and need for awareness of serious side effects.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"9a521120b00db5003e950bcc79b88131f8747109e7a00685c0b4fc8c39985b65"},{"id":"s2","type":"clinical_trial","url":"https://www.trialx.com/clinical-trials/listings/337033/melanotan-ii-mt-ii-as/","title":"Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","quote":"This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo. ... Recruiting","summary":"May 2026 listing of ongoing Phase 2 RCT (NCT07437560) testing MT-II safety and efficacy as add-on to phototherapy for vitiligo repigmentation.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"38b23f3fc8a365505b1aea535c189a4797f24e7c9c421d41f17c4d542f90237c"},{"id":"s3","type":"medical","url":"https://www.sciencedirect.com/science/article/pii/S2352512626002766","title":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use","quote":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. ... Melanotan I primarily targets MC1R, whereas melanotan II is a nonselective agonist with broader systemic effects","summary":"2026 case report of multiple primary melanomas in situ associated with recent Melanotan (II) exposure along with other risk factors.","claim_ids":["c3"],"link_status":"http_400","quote_status":"unverified","hash":"10edff64ddcdc5c655638f4014c88ae8a08808f8dfbcd843f118e1e70c364ecc"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41752902/","title":"Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report","quote":"This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect.","summary":"2026 case report documenting oral mucosal pigmentation changes following Melanotan II use, with follow-up observations on resolution after discontinuation.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"bde45647758fb70bfbb5a2acef6146e491a1a7bda5f51eea022cec607d6cb95b"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40210573/","title":"Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?","quote":"The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. ... Histological analysis confirmed the diagnosis of a mucosal malignant melanoma.","summary":"2025 case report linking Melanotan II nasal spray use to oral mucosal malignant melanoma in a young female; highlights unlicensed status and need for awareness of serious side effects.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"9a521120b00db5003e950bcc79b88131f8747109e7a00685c0b4fc8c39985b65"},{"id":"s2","type":"clinical_trial","url":"https://www.trialx.com/clinical-trials/listings/337033/melanotan-ii-mt-ii-as/","title":"Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","quote":"This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo. ... Recruiting","summary":"May 2026 listing of ongoing Phase 2 RCT (NCT07437560) testing MT-II safety and efficacy as add-on to phototherapy for vitiligo repigmentation.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"38b23f3fc8a365505b1aea535c189a4797f24e7c9c421d41f17c4d542f90237c"},{"id":"s3","type":"medical","url":"https://www.sciencedirect.com/science/article/pii/S2352512626002766","title":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use","quote":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. ... Melanotan I primarily targets MC1R, whereas melanotan II is a nonselective agonist with broader systemic effects","summary":"2026 case report of multiple primary melanomas in situ associated with recent Melanotan (II) exposure along with other risk factors.","claim_ids":["c3"],"link_status":"http_400","quote_status":"unverified","hash":"10edff64ddcdc5c655638f4014c88ae8a08808f8dfbcd843f118e1e70c364ecc"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41752902/","title":"Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report","quote":"This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect.","summary":"2026 case report documenting oral mucosal pigmentation changes following Melanotan II use, with follow-up observations on resolution after discontinuation.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"bde45647758fb70bfbb5a2acef6146e491a1a7bda5f51eea022cec607d6cb95b"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"melanotan-ii","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":4,"anecdotal":0,"scientific":4,"user_reports":0,"questions":0,"evidence_ingests":0}}